^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Excerpt:
...- Participants with either unresectable Stage IIIc or Stage IV metastatic melanoma positive for the BRAF V600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a Deoxyribonucleic acid (DNA) sequencing method, and who have...
Trial ID:
Source:
Title:
Treatment of patients with advanced melanoma with chemotherapy + Interferon combined with vemurafenib (BRAF-mutation positive patients) or chemotherapy +Interferon (BRAF-mutation negative patients) Paikallisesti levinneen tai etäpesäkkeitä lähettäneen melanooman hoito yhdistelmäsytostaattihoidolla ja interferonilla sekä vemurafenibilla (BRAF-mutaatio positiiviset potilaat) tai ilman (BRAF-mutaatio negatiiviset potilaat)
Excerpt:
...BRAF mutation status should be analysed; if technically not possible the patient is treated as BRAF negative 6. ...
Trial ID:
More C2 evidence
Source:
Title:
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
Excerpt:
...- Participants with age greater than or equal to (>=) 18 years with either unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF...
Trial ID:
Source:
Title:
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Excerpt:
...- Patients with histologically confirmed metastatic melanoma (surgically incurable and unresectable stage IIIC or stage IV; AJCC) with documented BRAF V600 mutation determined by the cobas® BRAF V600 Mutation Test prior to administration of vemurafenib....
Trial ID:
Source:
Title:
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
Excerpt:
...- BRAF V600 mutation status of the current primary tumor or involved lymph node determined to be positive using the cobas BRAF V600 mutation test...
Trial ID:
Source:
Title:
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Excerpt:
...- Positive BRAF V600 mutation result determined by a designated laboratory using the Cobas 4800 BRAF V600 Mutation Test...
Trial ID:
Source:
Title:
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Excerpt:
...Histologic diagnosis of unresectable stage IIIC or stage IV melanoma that is BRAF V600 mutation positive 4....
Trial ID:
Source:
Title:
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
Excerpt:
...- BRAF mutation detected by DNA sequencing of exon 15....
Trial ID:
Source:
Title:
An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
Excerpt:
...- Diagnosis of BRAF-V600 mutation-positive unresectable or metastatic melanoma confirmed by a validated test and being treated with vemurafenib...
Trial ID:
Source:
Title:
A Study of Vemurafenib in Participants With Metastatic Melanoma
Excerpt:
...- Participants with Histologically confirmed metastatic melanoma (surgically incurable and unresectable Stage IIIC or Stage IV; AJCC) with BRAF V 600 mutation determined by Cobas 4800 BRAF Mutation Test....
Trial ID:
Source:
Title:
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Excerpt:
...- Participants with either unresectable or metastatic melanoma positive for the BRAF^V600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, and for whom vemurafenib is an accepted standard of care or where there is...
Trial ID:
Source:
Title:
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
Excerpt:
...- Positive tested for BRAF mutation...
Trial ID:
Source:
Title:
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
Excerpt:
...- Metastatic melanoma (Stage IV, American Joint Committee on Cancer) with BRAF mutation (cobas 4800 BRAF V600 Mutation Test)...
Trial ID:
Source:
Title:
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Excerpt:
...- Melanoma must be documented to contain a BRAF V600 mutation by a CLIA approved assay...
Trial ID:
Source:
Title:
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
Excerpt:
...- Unresectable Stage IIIc or IV metastatic melanoma positive for the BRAFV600 mutation or other malignant tumor type which harbors a V600 activating mutation of BRAF, as determined by Cobas 4800 BRAFV600 Mutation Test or a DNA sequencing method...
Trial ID:
Source:
Title:
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Excerpt:
...- Patients with either unresectable Stage IIIc or Stage IV metastatic melanoma positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a DNA sequencing method, and who have...
Trial ID:
Source:
Title:
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Excerpt:
...- Positive proto-oncogene B-Raf (BRAF) mutation result (Cobas 4800 BRAF V600 Mutation Test)...
Trial ID:
Source:
Title:
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Excerpt:
...- Patients with either unresectable Stage IIIc or Stage IV metastatic melanoma positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a DNA sequencing method, and who have...
Trial ID:
Source:
Title:
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Excerpt:
...- Unresectable / metastatic BRAF-mutated melanomas, progressing on BRAF inhibitor after...
Trial ID:
Source:
Title:
A multicenter phase II study evaluating the effect and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with metastatic melanoma positive for the BRAF-mutation En multicenter fase II undersøgelse af vemurafenib i kombination med Pegyleret Interferon og Interleukin-2 til patienter med BRAF-muteret metastatisk malignt melanom
Excerpt:
...•Histologically verified unresectable stage III or stage IV melanoma with documented BRAF V600 mutation determined by the cobas® 4800 BRAF mutation test •Age between 18 and 70 •ECOG performance status (PS) 0-2 •Patients must have measurable target lesions disease as defined by RECIST v1.1 •Prior medical treatment for metastatic melanoma is allowed, except previous treatment with BRAF-inhibitor and IL-2 based immunotherapy •Adequate cardiac function (less or equal to NYHA II). ...
Trial ID:
Less C2 evidence
Source:
Title:
Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
Published date:
01/19/2023
Excerpt:
We found that the addition of an EZH2 inhibitor to vemurafenib improved the response of melanoma cells resistant to BRAFi...When we inhibited both BRAF and PLK1, we achieved an improved response of BRAFi-resistant melanoma cells, which was comparable to the combined inhibition of BRAF and EZH2. These results thus reveal that targeting EZH2 or its downstream targets, such as PLK1, in combination with BRAF inhibitors are potential novel therapeutic options in melanomas with BRAF mutations.
Secondary therapy:
EZH2 inhibitor
DOI:
10.3390/ijms24031963